Nordicus Partners Corporation Corporate Update

Impact · against what's priced in

Nordicus Partners shows positive momentum through clinical de-risking across three pipeline candidates and progress toward a Nasdaq uplisting. The most material catalyst is the transition of QR-01 from successful animal studies to a scheduled Phase IIa human trial in early 2027.

NORD+0.70

No priced-in read yet

In context

The company has validated QR-01 efficacy in beagle and rat studies, enabling a Phase IIa start in H1 2027, and received a toxicity waiver for QR-02. Additionally, the ongoing process to move shares from OTCQB to a major exchange typically improves institutional access.

Read from the article alone

• pharmaceuticals
• NORD
• biotechnology
• clinical trials
• corporate update
• life sciences
• nasdaq uplist
• oral cancer
• periodontitis
• psoriasis

Search tags